To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Ability to understand and willingness to sign informed consent.
Age ≥18 years.
Has histologically confirmed metastatic or advanced unresectable cholangiocarcinoma.
Has disease that is measurable per the RECIST v1.1.
Received prior chemotherapy, biologic therapy, immunotherapy, or investigational agent within 3 weeks prior to initiation of study medications.
Had previous treatment with selective FGFR inhibitors including erdafitinib, infigratinib, or futibatinib.
Had prior therapy with any VEGFR-targeting agent targeting including bevacizumab, ramucirumab, pazopanib, lenvatinib, and other anti-angiogenesis inhibitors.
Has a history and/or has current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system, and lung. Exceptions include calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcifications-these are allowed.
Single group
Pemigatinib
DrugGiven by PO
Atezolizumab
DrugGiven by PO and IV
Bevacizumab
DrugGiven by PO and IV
Safety and adverse events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
